01/03/2024 - 15:53

Terbium emerging as cancer-fighting key for Radiopharm

01/03/2024 - 15:53


Upgrade your subscription to use this feature.

Radiopharm Theranostics says a new six-patient study shows its terbium-based treatment has superior potential to tackle prostate cancer than lutetium following a head-to-head assessment of the rare earths metals in its therapies. Management says the results from tests on patients with metastatic “castrate-resistant” cancer vindicate its development of next-generation, terbium-based radiotherapies for the treatment of the often deadly condition and other advanced cancers.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options